• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.40 In stock
5 mg $218.70 In stock
10 mg $337.40 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2

Purity

≥98%

Formula

C27H20ClFN4O4

Formula Wt.

518.92

IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid

Synonym

Alisertib

Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble

Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF

Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • R3347

    Riluzole

    Benzothiazole; TRPC5 agonist, PTR1 inhibitor, v...

    ≥98%
  • T0090

    7-(Triethylsilyl)-baccatin III

    Synthetic taxol synthesis intermediate; microtu...

    ≥98%
  • A044178

    Abemaciclib mesylate

    CDK inhibitor.

    ≥98%
  • S8013

    [Tyr8]-Substance P

    Endogenous tachykinin peptide, involved in infl...

    ≥95%
  • T3134

    Thiostrepton

    Thiazole; proteasome inhibitor, protein translo...

    ≥97%, HPLC
  • C5260

    C-type Natriuretic Peptide (1-22), pig/human/rat

    Endogenous cardiomodulatory peptide; NPR-B agon...

    ≥95%
  • R5700

    Ro 61-8048

    Kynurenine 3-hydroxylase inhibitor.

    ≥99%
  • D3212

    2′,3′-Dideoxycytidine

    Pyrimidine nucleoside (cytidine) analog; DNA ch...

    ≥98%
  • C0271

    Carfilzomib

    Epoxomicin analog; proteasome inhibitor.

    ≥98%
  • B8112

    Budesonide

    Steroid; glucocorticoid agonist.

    ≥97%
  • N0161

    β-Naphthoflavone

    AhR agonist.

    ≥98%
  • N3210

    Nicergoline

    Ergot derivative found in Claviceps; α1-adrene...

    ≥98%
  • B4518

    Bleomycin Sulfate

    Mixture of glycopeptide bleomycin sulfate salts...

    ≥90%
  • K040007

    KB-0742

    CDK9 inhibitor.

    ≥98%
  • C000171

    C-171

    STING inhibitor

    ≥98%
  • E6996

    Erythromycin Thiocyanate

    Macrolide; protein translation inhibitor, mamma...

    ≥90%
  • L8262

    Lupinine

    Alkaloid found in species of Loranthus, Calia, ...

    ≥98%
  • S1604

    Secretin Acetate

    Endogenous peptide hormone, involved in feeding...

    ≥95%
  • R1879

    Retinyl Palmitate

    Vitamin A derivative, palmitic acid ester of re...

    ≥1.70 MIU/g, bio assay
  • T3585

    Tivozanib

    VEGFR1/2/3, c-Kit, PDGFR inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only